Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

• Status: Completed
• Trial end date: 2018-09-05
• Target enrollment: 0
• Participant gender: Female

Summary

To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medy-Tox
• Treatments: Botulinum Toxins, Type A

Criteria

Inclusion Criteria:

• Female aged more than 20 years

• Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening

Exclusion Criteria:

• Patient not appropriate for participating in this study according to the investigator's opinion